Skip to main content
    A

    Amgen Inc (AMGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $444.63
    +5.37 (+1.22%)

    Market Cap: $237.48B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    92%(36/39)
    Avg Surprise
    +6.80%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$5.79
    Range$5.47 - $6.09
    28 analysts
    EPS Revisions
    2
    0
    7d
    2
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$5.74+0.8%
    60d ago$5.78+0.1%
    30d ago$5.78+0.1%
    7d ago$5.76+0.5%
    Current$5.79
    Revenue Consensus
    $10.1B
    Range$9.8B - $10.3B
    25 analysts
    Period ending Dec 31, 2026
    EPS Consensus$6.86
    Range$6.32 - $7.27
    33 analysts
    Revenue Consensus
    $10.9B
    Range$10.3B - $11.4B
    31 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$6.86---
    Sep 26EST
    		-$5.79---
    Jun 26
    Reported Aug 4
    		$6.29$5.60+12.32%Beat+4.5%
    Mar 26
    Reported Apr 30
    		$5.15$4.77+7.97%Beat+5.1%
    Dec 25
    Reported Feb 3
    		$5.29$4.73+11.84%Beat-0.4%
    Sep 25
    Reported Nov 4
    		$5.64$5.01+12.57%Beat+1.1%
    Jun 25
    Reported Aug 5
    		$6.02$5.28+14.02%Beat+21.1%
    Mar 25
    Reported May 1
    		$4.90$4.26+15.02%Beat+23.7%
    Dec 24
    Reported Feb 4
    		$5.31$5.08+4.53%Beat+12.7%
    Sep 24
    Reported Oct 30
    		$5.58$5.11+9.20%Beat+12.5%
    Jun 24
    Reported Aug 6
    		$4.97$5.00-0.60%Miss-0.6%
    Mar 24
    Reported May 2
    		$3.96$3.89+1.80%Beat-0.5%
    Dec 23
    Reported Feb 6
    		$4.71$4.59+2.61%Beat+15.2%
    Sep 23
    Reported Oct 31
    		$4.96$4.68+5.98%Beat+5.5%
    Jun 23
    Reported Aug 3
    		$5.00$4.49+11.36%Beat+7.5%
    Mar 23
    Reported Apr 27
    		$3.98$3.85+3.38%Beat-6.4%
    Dec 22
    Reported Jan 31
    		$4.09$4.09+0.00%Beat-6.2%
    Sep 22
    Reported Nov 3
    		$4.70$4.45+5.62%Beat+0.6%
    Jun 22
    Reported Aug 4
    		$4.65$4.33+7.39%Beat+6.2%
    Mar 22
    Reported Apr 27
    		$4.25$4.12+3.16%Beat+14.9%
    Dec 21
    Reported Feb 7
    		$4.36$4.04+7.92%Beat+14.4%
    Sep 21
    Reported Nov 2
    		$4.67$4.22+10.66%Beat+6.9%
    Jun 21
    Reported Aug 3
    		$4.38$4.01+9.23%Beat+3.1%
    Mar 21
    Reported Apr 27
    		$3.70$4.04-8.42%Miss-11.3%
    Dec 20
    Reported Feb 2
    		$3.81$3.35+13.73%Beat+4.7%
    Sep 20
    Reported Oct 28
    		$4.37$3.75+16.53%Beat+19.4%
    Jun 20
    Reported Jul 28
    		$4.25$3.77+12.73%Beat+7.1%
    Mar 20
    Reported Apr 30
    		$4.17$3.75+11.20%Beat+17.1%
    Dec 19
    Reported Jan 30
    		$3.64$3.42+6.43%Beat+6.4%
    Sep 19
    Reported Oct 29
    		$3.66$3.53+3.68%Beat-0.8%
    Jun 19
    Reported Jul 30
    		$3.97$3.58+10.89%Beat+3.7%
    Mar 19
    Reported Apr 30
    		$3.56$3.48+2.30%Beat+2.6%
    Dec 18
    Reported Jan 29
    		$3.42$3.27+4.59%Beat+18.3%
    Sep 18
    Reported Oct 30
    		$3.69$3.45+6.96%Beat+12.8%
    Jun 18
    Reported Jul 26
    		$3.83$3.56+7.58%Beat+17.1%
    Mar 18
    Reported Apr 24
    		$3.47$3.25+6.77%Beat+10.2%
    Dec 17
    Reported Feb 1
    		$2.89$3.03-4.62%Miss+0.0%
    Sep 17
    Reported Oct 25
    		$3.27$3.10+5.48%Beat-
    Jun 17
    Reported Jul 25
    		$3.27$3.11+5.14%Beat-
    Mar 17
    Reported Apr 26
    		$3.15$3.01+4.65%Beat-
    Dec 16
    Reported Feb 2
    		$2.89$2.79+3.58%Beat-

    Dividends

    Dividend Metrics

    Forward Yield2.27%
    Forward Annual Dividend$10.08
    Payout Ratio43.02%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+7.05%
    5Y CAGR+8.27%
    AMGN dividend history and ex-dividend datesRun AMGN in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio19.88EV/EBITDA16.08x
    Price/FCF23.60xFCF Yield4.24%
    Profitability
    Profit Margin23.00%Operating Margin35.50%
    ROE91.50%ROIC15.96%
    Financial Health
    Debt/Equity4.90xInterest Coverage4.86x
    Current Ratio1.37xQuick Ratio1.13x
    Trading Statistics
    Beta0.41Avg Volume2.72M
    52-Week High$450.9852-Week Low$280.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$433.89
    SMA 20$422.64
    SMA 50$417.65
    SMA 200$369.71
    EMA 10$434.41
    EMA 20$426.08
    EMA 50$413.50
    EMA 200$373.46

    MACD

    Line: 9.43Signal: 6.83Hist: 2.60

    ADX

    ADX: 27.8+DI: 35.4-DI: 13.8

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$410.33

    Bollinger Bands

    Upper Band$451.80
    Lower Band$393.48
    %B Position1380%(Upper)
    Band Width0.88

    RSI (14-Day)

    Neutral
    63.2

    Momentum Oscillators

    Stoch %K86.5
    Stoch %D89.3
    Williams %R-12.5
    ROC (10d)6.5%
    Momentum27.06
    CCI (20d)119.8
    MFI (14d)67.1

    Volatility Measures

    ATR (14d)$10.60(2.4%)
    StdDev (20d)14.58
    Hist Vol28.8%(Moderate)

    Volume Flow

    VWAP$444.64
    OBV65.6M
    AD Line-788.8M
    CMF (20d)-0.023

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio0.7x
    VWMA (20d)$422.82

    Pivot Points

    R3$448.40
    R2$446.49
    R1$442.88
    Pivot Point$440.97
    S1$437.36
    S2$435.45
    S3$431.84

    Advanced Oscillators

    TSI21.07
    Ultimate Osc53.5
    KST52.41

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$10.05B$8.62B$9.87B$9.56B$9.18B$8.15B$9.09B$8.50B$8.39B$7.45B$8.20B$6.90B
    Cost of Revenue$2.81B$2.74B$2.98B$3.08B$3.01B$2.97B$3.11B$3.31B$3.24B$3.20B$3.11B$1.81B
    Gross Profit$7.24B$5.87B$6.89B$6.47B$6.17B$5.18B$5.97B$5.19B$5.15B$4.25B$5.08B$5.10B
    Operating Expenses$3.73B$3.21B$4.17B$3.95B$3.51B$4.00B$3.66B$3.15B$3.24B$3.26B$3.81B$3.08B
    R&D$1.87B$1.72B$2.14B$1.90B$1.74B$1.49B$1.72B$1.45B$1.45B$1.34B$1.53B$1.08B
    SG&A$1.75B$1.60B$2.03B$2.05B$1.69B$1.69B$1.94B$1.70B$1.80B$1.91B$3.15B$1.35B
    Operating Income$3.51B$2.67B$2.72B$2.53B$2.66B$1.18B$2.31B$2.05B$1.91B$991.00M$1.27B$2.02B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$673.00M$657.00M$653.00M$685.00M$694.00M$723.00M$747.00M$776.00M$808.00M$824.00M$821.00M$759.00M
    Income Before Tax$2.77B$2.08B$1.51B$3.92B$1.57B$1.97B$782.00M$3.10B$794.00M$-68,000,000$852.00M$1.95B
    Income Tax Expense$393.00M$265.00M$181.00M$705.00M$136.00M$243.00M$155.00M$271.00M$48.00M$45.00M$85.00M$217.00M
    Net Income$2.38B$1.82B$1.33B$3.22B$1.43B$1.73B$627.00M$2.83B$746.00M$-113,000,000$767.00M$1.73B
    EBITDA$4.55B$3.86B$3.30B$5.91B$3.60B$4.08B$2.93B$5.27B$3.00B$2.15B$3.05B$3.60B
    EBIT$3.44B$2.74B$2.17B$4.61B$2.26B$2.70B$1.53B$3.88B$1.60B$756.00M$1.67B$2.71B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789...

    Glenn Ford
    •
    2/27/26
    •
    186
    Biotech, BioPharma
    Also mentions:
    SNYAMGNTMDXGILD

    Government Contracts

    Gov Obligations (TTM)
    $2.28M
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    0
    Avg Remaining Term
    18.2 mo

    Top agency: Department of Health and Human Services at 100.0% of trailing twelve month obligations across 1 agencies

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Nautilus Biotechnology joins ARPA-H-funded Alzheimer's research group

    Nautilus Biotechnology (NASDAQ: NAUT) has joined the SEEDS consortium, an ARPA-H-funded program focused on Alzheimer's disease and Ewing sarcoma research. Nautilus will receive up to $6 million to utilize its Voyager...

    StreetInsider•10/27/26•Somewhat-Bullish

    Amgen appoints former Yum! Brands CEO to board of directors By Investing.com

    Amgen has announced the appointment of David W. Gibbs, former president and CEO of Yum! Brands, to its board of directors. Gibbs will serve on the Audit Committee and Compensation and Management Development Committee....

    Investing.com Canada•10/27/26•Somewhat-Bullish

    How EU Label Expansion Will Impact Ionis Stock

    Ionis Pharmaceuticals received a positive opinion from the EMA's CHMP for an expanded indication of TRYNGOLZA in the EU for severe hypertriglyceridemia...

    Simply Wall Street•10/27/26•Neutral

    Amgen Inc. $AMGN Stock Bought by Apollon Wealth Management LLC

    Apollon Wealth Management LLC increased its stake in Amgen Inc. by 10.2% in the third quarter, bringing its total holdings to 25,739 shares valued at $10.85 million. This news comes as Amgen reported positive lung-cancer...

    MarketBeat•10/27/26•Somewhat-Bullish

    Second Medical Use Claims Before the UPC: Proving the Therapeutic Purpose

    The Düsseldorf Local Division of the Unified Patent Court recently addressed the challenge of proving infringement for second medical use claims...

    Wolters Kluwer•10/27/26•Neutral

    AMGN Valuation and Fair Value

    P/E
    19.9x
    Forward P/E
    15.6x
    EV/EBITDA
    16.1x
    P/FCF
    23.6x
    PEG
    2.3x
    P/B
    20.5x
    See GNG's fair value

    AMGN Profitability: Margins, ROIC and FCF

    Gross margin
    69.5%
    Operating margin
    35.5%
    Net margin
    23.0%
    ROIC
    16.0%
    ROE
    91.5%
    FCF margin
    26.7%
    FCF yield
    4.2%

    AMGN Competitors

    CompanyTicker
    Thermo Fisher Scientific IncTMO
    Gilead Sciences IncGILD
    AstraZeneca PLCAZN
    Abbott LaboratoriesABT
    Novartis AG ADRNVS
    Novo Nordisk A/SNVO
    Merck & Company IncMRK
    Pfizer IncPFE

    Sector: Healthcare

    AMGN Analyst Ratings

    Consensus
    Hold
    Analysts
    34
    Strong Buy
    4
    Buy
    8
    Hold
    17
    Sell
    3
    Strong Sell
    2

    AMGN Bull Case vs Bear Case

    Bull case

    • AMGN earns a 16.0% return on invested capital.
    • AMGN converts 26.7% of revenue into free cash flow.
    • AMGN has a 23.0% net profit margin.

    Bear case

    • AMGN has a debt-to-equity ratio of 4.9x.

    AMGN Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    10.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $5.79
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 3 down

    AMGN Dividend

    Forward yield
    2.3%
    Payout ratio
    43.0%
    3Y DPS growth
    7.1%
    5Y DPS growth
    8.3%
    Pay months
    Mar, Jun, Sep, Dec
    AMGN dividend history

    Frequently Asked Questions About AMGN

    What is AMGN's current dividend yield?

    Amgen Inc (AMGN) has a forward dividend yield of 2.27%.

    Does AMGN pay dividends?

    Yes, Amgen Inc pays dividends with a forward dividend yield of 2.27%.

    What is AMGN's P/E ratio?

    Amgen Inc has a price-to-earnings (P/E) ratio of 19.88.

    What is AMGN's market cap?

    Amgen Inc (AMGN) has a market capitalization of $237.48B with a current stock price of $444.63.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In